Researchers link SARS-CoV-2 PLpro to COVID-19 symptoms
Researchers have shown that the SARS-CoV-2 PLpro cuts human proteins so could potentially cause a range of COVID-19 symptoms.
List view / Grid view
Researchers have shown that the SARS-CoV-2 PLpro cuts human proteins so could potentially cause a range of COVID-19 symptoms.
Complete solutions for neurological disease research and discovery - helping you to better understand diseases to improve patient outcomes.
Analysis of one million SARS-CoV-2 genome sequences has revealed a new variant named T478K, spreading mostly in Mexico.
Learn about a practical, high-throughput method for validating the target-specificity of antibodies for the application of western blot.
Scientists have shown that trapped LC3B protein in brain cells enables Parkinson's disease to spread, presenting a drug target.
25 May 2021 | By Metabolon
Discover how metabolomics can support your biomarker strategy in drug development and clinical trials in this on-demand webinar.
A new modelling method could be used as a surveillance tool to monitor emerging infectious SARS-CoV-2 variants, scientists say.
A team has shown that the NapA protein, associated with Lyme disease, attracts inflammatory molecules in the body.
Our comprehensive portfolio suite is designed to optimize your productivity to get safe and efficacious vaccines and therapeutics to market faster.
Researchers have designed a new nanoparticle-based vaccine against Ebola that has shown promise in mice and rabbits.
Researchers have found that a metabolite of remdesivir potentially targets a SARS-CoV-2 protein involved in suppressing the host cell's defence response.
11 May 2021 | By PerkinElmer
Get the Big Picture and listen to Pharma thought leaders how they view CETSA® and its impact on their Drug Discovery.
Researchers have produced a computational simulation of the SARS-CoV-2 Spike protein, finding spots that glycans do not cover.
Researchers have found that over 80 percent of antibodies target sections of the SARS-CoV-2 Spike protein other than the RBD.
Gain more insight into immune-tumor interactions and learn how antibody detection techniques like multiplexing is advancing immunotherapies.